Abstract: Described is the use of a first antibody molecule that specifically binds Fc?RIIb via its Fab region, but lacks Fc region or has reduced binding to Fc? receptors via its Fc region, for use in combination with a second antibody molecule that specifically binds to a receptor present on an immune cell, wherein the immune cell is an immune cell that suppresses anti-cancer immunity, which second antibody molecule has an Fc region that binds to at least one activating Fc? receptor, and wherein the binding of the second antibody molecule to the receptor on the immune cell causes depletion and/or deactivation of the immune cell in the treatment of an Fc?RIIb-negative cancer in a patient, as well as pharmaceutical compositions and kits comprising these to antibody molecules, and methods of treating cancer using these two antibodies.

Abstract: Described is the use of a first antibody molecule that specifically binds Fc?RIIB via its Fab region, but lacks Fc region or has reduced binding to Fc? receptors via its Fc region, for use in combination with a second antibody molecule that specifically binds to a receptor present on a tumor cell, which second antibody molecule has an Fc region that binds to at least one activating Fc? receptor in the treatment of an Fc?RIIB-negative cancer in a patient, as well as pharmaceutical compositions and kits including these two antibody molecules, and methods of treating cancer using these two antibodies.

Abstract: Described is the use of a first antibody molecule that specifically binds Fc?RIIb via its Fab region, but lacks Fc region or has reduced binding to Fc? receptors via its Fc region, for use in combination with a second antibody molecule that specifically binds to a receptor present on an immune cell, wherein the immune cell is an immune cell that suppresses anti-cancer immunity, which second antibody molecule has an Fc region that binds to at least one activating Fc? receptor, and wherein the binding of the second antibody molecule to the receptor on the immune cell causes depletion and/or deactivation of the immune cell in the treatment of an Fc?RIIb-negative cancer in a patient, as well as pharmaceutical compositions and kits comprising these to antibody molecules, and methods of treating cancer using these two antibodies.

Abstract: The present invention generally relates to antibody combinations and uses thereof.

Abstract: Described is the combined use of a first antibody molecule that specifically binds FcyRIIb via its Fab region and that binds an Fey receptor via its Fc region, and a second antibody molecule that specifically binds PD-1 and that binds at least one Fey receptor via its Fc region, in the treatment of cancer in a patient having tumor infiltrating T lymphocytes with a medium or high PD-1 expression, as well as pharmaceutical compositions and kits comprising these two antibody molecules, and methods of treating cancer using these two antibodies. Described is also a diagnostic test for identification of patients benefitting from the treatment described herein.

Abstract: Described is the use of a first antibody molecule that specifically binds Fc?RIIb via its Fab region, but lacks Fc region or has reduced binding to Fc? receptors via its Fc region, for use in combination with a second antibody molecule that specifically binds to a receptor present on an immune cell, wherein the immune cell is an immune cell that suppresses anti-cancer immunity, which second antibody molecule has an Fc region that binds to at least one activating Fc? receptor, and wherein the binding of the second antibody molecule to the receptor on the immune cell causes depletion and/or deactivation of the immune cell in the treatment of an Fc?RIIb-negative cancer in a patient, as well as pharmaceutical compositions and kits comprising these to antibody molecules, and methods of treating cancer using these two antibodies.

Abstract: Disclosed is a device for controlled separation of a first so-called stationary part and a second so-called mobile part, the stationary part having a stationary connecting surface opposite a mobile connecting surface of the mobile part, the stationary part having a different thermal expansion coefficient from that of the mobile part, the separation device including: at least one connecting agent arranged in a layer between the stationary connecting surface and the mobile connecting surface, at least one device for heating at least one of the stationary part and the mobile part, and at least one system for controlling the heating device.

Abstract: Disclosed is a device for controlled separation of a first so-called stationary part and a second so-called mobile part, the stationary part having a stationary connecting surface opposite a mobile connecting surface of the mobile part, the stationary part having a different thermal expansion coefficient from that of the mobile part, the separation device including: at least one connecting agent arranged in a layer between the stationary connecting surface and the mobile connecting surface, at least one device for heating at least one of the stationary part and the mobile part, and at least one system for controlling the heating device.

Abstract: Devices and methods of commodity usage monitoring determine the amount of commodity used by individual elements of multi-element systems having a common source. An amount of commodity drawn from the source by all the users is determined. A user-state that indicates use of the commodity by each user is determined. Individual user consumption of the commodity for each of the users is determined using repeated determinations of the amount of the commodity and the user-state, for a number of repetitions greater than or equal to the number of users. Determining individual consumption can be performed using minimum least square estimation, singular value decomposition, discriminant function analysis, or other computational or analytical solution method. Duration and consumption information can be used to calculate the total amount of the commodity consumed by the particular user. Useful commodities include, but are not limited to, gas, electricity, mechanical, pneumatic, hydraulic, and water.

Abstract: A storage and delivery device for a cryogenic liquid that includes a vessel assembly and a delivery line assembly. The vessel assembly has a liquid space and a vapor space. The delivery line assembly has a liquid line, a vapor line, and a delivery line. The liquid line is in fluid communication with the liquid space. The vapor line is in fluid communication with the vapor space. The liquid line has a flow control device located thereon and structured to control the flow of fluid through the liquid line. The liquid line flow control device is structured to close the liquid line when the vessel assembly is at a predetermined pressure.